Press Releases | BioNTech

28 March 2023

BioNTech Announces New ADS Repurchase Program

27 March 2023

BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

20 March 2023

BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications

Read on

14 March 2023

Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years

Read on

13 March 2023

Update on First BioNTainer for African-based mRNA Manufacturing Facility

Read on

13 March 2023

BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023

Read on

1 March 2023

BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel

Read on

1 March 2023

Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years

Read on

24 February 2023

Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine for Ages 12 Years and Older as Primary Series or Booster

Read on

10 February 2023

Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based Shingles Vaccine Program

Read on

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. BioNTech disavows any obligation to update the information contained in such press releases after the date of their issuance.